These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31208737)

  • 21. Risankizumab for the treatment of psoriasis.
    Gu C; Yang J
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):851-857. PubMed ID: 31460804
    [No Abstract]   [Full Text] [Related]  

  • 22. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
    Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
    N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of biologics in psoriasis.
    Kamata M; Tada Y
    J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.
    Arakawa A; Ruzicka T; Prinz JC
    JAMA Dermatol; 2016 Jul; 152(7):825-8. PubMed ID: 27096382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma.
    Wang DM; Fernandez AP; Calabrese CM; Calabrese LH
    Clin Exp Dermatol; 2019 Jan; 44(1):113-115. PubMed ID: 29797733
    [No Abstract]   [Full Text] [Related]  

  • 26. Ustekinumab: The "New Kid on the Block" in the Treatment of Psoriatic Arthritis.
    Torres T; Faria R
    Drug Dev Res; 2015 Dec; 76(8):428-31. PubMed ID: 26372543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
    Leonardi CL; Kimball AB; Papp KA; Yeilding N; Guzzo C; Wang Y; Li S; Dooley LT; Gordon KB;
    Lancet; 2008 May; 371(9625):1665-74. PubMed ID: 18486739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
    Papp KA; Langley RG; Lebwohl M; Krueger GG; Szapary P; Yeilding N; Guzzo C; Hsu MC; Wang Y; Li S; Dooley LT; Reich K;
    Lancet; 2008 May; 371(9625):1675-84. PubMed ID: 18486740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.
    Scanlon JV; Exter BP; Steinberg M; Jarvis CI
    Ann Pharmacother; 2009 Sep; 43(9):1456-65. PubMed ID: 19671802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.
    Yeilding N; Szapary P; Brodmerkel C; Benson J; Plotnick M; Zhou H; Goyal K; Schenkel B; Giles-Komar J; Mascelli MA; Guzzo C
    Ann N Y Acad Sci; 2011 Mar; 1222():30-9. PubMed ID: 21434940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis.
    Chiu HY; Wang TS; Chan CC; Cheng YP; Lin SJ; Tsai TF
    Br J Dermatol; 2014 Nov; 171(5):1181-8. PubMed ID: 24734995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.
    Tsai TF; Ho V; Song M; Szapary P; Kato T; Wasfi Y; Li S; Shen YK; Leonardi C;
    Br J Dermatol; 2012 Nov; 167(5):1145-52. PubMed ID: 22803615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Secukinumab].
    Meunier L;
    Ann Dermatol Venereol; 2019; 146(6-7):503-506. PubMed ID: 31204124
    [No Abstract]   [Full Text] [Related]  

  • 34. [Ixekizumab].
    Seneschal J;
    Ann Dermatol Venereol; 2019; 146(6-7):507-510. PubMed ID: 31204120
    [No Abstract]   [Full Text] [Related]  

  • 35. [Infliximab].
    Goujon C; Bachelez H;
    Ann Dermatol Venereol; 2019; 146(6-7):483-486. PubMed ID: 31230775
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
    van Vollenhoven RF; Hahn BH; Tsokos GC; Wagner CL; Lipsky P; Touma Z; Werth VP; Gordon RM; Zhou B; Hsu B; Chevrier M; Triebel M; Jordan JL; Rose S
    Lancet; 2018 Oct; 392(10155):1330-1339. PubMed ID: 30249507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Brodalumab].
    Girard C;
    Ann Dermatol Venereol; 2019; 146(6-7):511-514. PubMed ID: 31204123
    [No Abstract]   [Full Text] [Related]  

  • 38. Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?
    Griffiths CE; Girolomoni G
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():2-8. PubMed ID: 22758911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic review of ustekinumab in the treatment of atopic dermatitis.
    Pan Y; Xu L; Qiao J; Fang H
    J Dermatolog Treat; 2018 Sep; 29(6):539-541. PubMed ID: 29164954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis.
    Zabotti A; Goletti D; Lubrano E; Cantini F
    Expert Opin Drug Saf; 2020 Jan; 19(1):69-82. PubMed ID: 31847608
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.